Y Intercept Hong Kong Ltd Has $2.85 Million Stock Holdings in Organon & Co. $OGN

Y Intercept Hong Kong Ltd lifted its holdings in shares of Organon & Co. (NYSE:OGN) by 17.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 476,488 shares of the company’s stock after buying an additional 70,326 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.18% of Organon & Co. worth $2,854,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in OGN. State of Alaska Department of Revenue grew its stake in Organon & Co. by 0.6% in the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after acquiring an additional 1,570 shares during the period. Integrated Wealth Concepts LLC lifted its position in Organon & Co. by 2.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock worth $626,000 after buying an additional 1,594 shares in the last quarter. Rafferty Asset Management LLC boosted its position in Organon & Co. by 8.5% during the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock valued at $228,000 after purchasing an additional 1,847 shares during the last quarter. Bank of Nova Scotia grew its stake in shares of Organon & Co. by 4.6% in the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company’s stock valued at $475,000 after buying an additional 1,947 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and upped their target price for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Finally, BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Organon & Co. presently has a consensus rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Down 0.4%

Shares of NYSE OGN opened at $13.51 on Wednesday. The company’s 50 day moving average price is $13.41 and its 200-day moving average price is $9.64. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.60. The company has a market capitalization of $3.55 billion, a P/E ratio of 14.52, a price-to-earnings-growth ratio of 1.26 and a beta of 1.54.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the company posted $1.02 earnings per share. Organon & Co.’s quarterly revenue was down 3.5% on a year-over-year basis. Equities analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were paid a $0.02 dividend. The ex-dividend date was Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio is currently 8.60%.

Insider Transactions at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur acquired 26,448 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were bought at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the transaction, the senior vice president owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This represents a 100.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.62% of the stock is owned by corporate insiders.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.